Ownership and insider activity for Hoth Therapeutics, Inc. (HOTH): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D.
Price
| Price | $0.80 |
| Market Cap | $11M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.2M | $282621 | $1.7M | $2.6M | $8.5M | $6.4M | $9.3M | $7.0M | $6.2M |
| Short-term Investments | 0 | 0 | $803664 | $2.1M | $1.9M | $209320 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | $50000 | 0 | 0 | $46769 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $1.2M | $501648 | $2.6M | $4.8M | $10.6M | $6.7M | $10.2M | $7.6M | $6.9M |
| Property, Plant & Equipment | $3492 | $2268 | $1043 | 0 | 0 | 0 | $55165 | $31075 | $4652 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $1.2M | $503916 | $2.8M | $5.2M | $11.0M | $6.8M | $10.2M | $7.7M | $7.6M |
| Accounts Payable | $47924 | $142280 | $403885 | $129469 | $360964 | $694989 | $35592 | $412071 | $823674 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $49466 | $348951 | $440121 | $312149 | $867787 | $1.4M | $678657 | $831197 | $1.5M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $49466 | $348951 | $440121 | $597149 | $1.1M | $1.6M | $704983 | $833906 | $1.5M |
| Retained Earnings | -$2.0M | -$4.5M | -$12.2M | -$19.4M | -$33.7M | -$45.1M | -$52.2M | -$60.4M | -$72.9M |
| Total Equity | $1.2M | $154965 | $2.4M | $4.6M | $9.9M | $5.1M | $9.5M | $6.9M | $6.2M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | $55165 | $31075 | $5678 |
| Net Debt | -$1.2M | -$282621 | -$2.5M | -$4.7M | -$10.4M | -$6.6M | -$9.2M | -$7.0M | -$6.2M |
| Working Capital | $1.2M | $152697 | $2.2M | $4.5M | $9.7M | $5.3M | $9.5M | $6.8M | $5.4M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 4.72 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -11.74 |
Profitability
| Return on Equity | -202.73% |
| Return on Invested Capital | -180.48% |
| Return on Assets | -164.00% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ASBP · BCTX · CRIS · DARE · ENTO · FBLG · LEXX
Explore sector: Healthcare · Biotechnology
More sections of HOTH: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks